AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

This was the ADR's second consecutive day of losses.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

AstraZeneca PLC AZN shares slid 1.44% to £106.62 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.46% to 8,834.03.